Evidence map›Paper›PMID 38977731›Full record

ArticleScientific reports2024

Modelling the lymphatic metastatic progression pathways of OPSCC from multi-institutional datasets.

Roman Ludwig, Adrian Daniel Schubert, Dorothea Barbatei, Lauence Bauwens, Jean-Marc Hoffmann, Sandrine Werlen, Olgun Elicin, Matthias Dettmer, Philippe Zrounba, Bertrand Pouymayou and 4 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Roman LudwigDep. of Radiation Oncology, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland. roman.ludwig@usz.ch.
Adrian Daniel SchubertDep. of ENT, Head & Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, 3010, Bern, Switzerland.
Dorothea BarbateiDep. of Radiation Oncology, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France.
Lauence BauwensDep. of Radiation Oncology, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France.
Jean-Marc HoffmannDep. of Radiation Oncology, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Sandrine WerlenDep. of ENT, Head & Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, 3010, Bern, Switzerland.
Olgun ElicinDep. of Radiation Oncology, Bern University Hospital, University of Bern, Freiburgstrasse 18, 3010, Bern, Switzerland.
Matthias DettmerInstitute of Tissue Medicine and Pathology, Bern University Hospital, University of Bern, Murtenstrasse 31, 3008, Bern, Switzerland.
Philippe ZrounbaDep. of Head and Neck surgery, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France.
Bertrand PouymayouDep. of Radiation Oncology, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Panagiotis BalermpasDep. of Radiation Oncology, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Vincent GrégoireDep. of Radiation Oncology, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France.
Roland GigerDep. of ENT, Head & Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, 3010, Bern, Switzerland.
Jan UnkelbachDep. of Radiation Oncology, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.

Funding

Swiss Cancer Research Foundation 5645-08-2022Universität Zürich Clinical Research Priority Program Artificial Intelligence in Oncological Imaging
6 · The paper itself

Abstract

The elective clinical target volume (CTV-N) in oropharyngeal squamous cell carcinoma (OPSCC) is currently based mostly on the prevalence of lymph node metastases in different lymph node levels (LNLs) for a given primary tumor location. We present a probabilistic model for ipsilateral lymphatic spread that can quantify the microscopic nodal involvement risk based on an individual patient's T-category and clinical involvement of LNLs at diagnosis. We extend a previously published hidden Markov model (HMM), which models the LNLs (I, II, III, IV, V, and VII) as hidden binary random variables (RVs). Each represents a patient's true state of lymphatic involvement. Clinical involvement at diagnosis represents the observed binary RVs linked to the true state via sensitivity and specificity. The primary tumor and the hidden RVs are connected in a graph. Each edge represents the conditional probability of metastatic spread per abstract time-step, given disease at the edge's starting node. To learn these probabilities, we draw Markov chain Monte Carlo samples from the likelihood of a dataset (686 OPSCC patients) from three institutions. We compute the model evidence using thermodynamic integration for different graphs to determine which describes the data best.The graph maximizing the model evidence connects the tumor to each LNL and the LNLs I through V in order. It predicts the risk of occult disease in level IV is below 5% if level III is clinically negative, and that the risk of occult disease in level V is below 5% except for advanced T-category (T3 and T4) patients with clinical involvement of levels II, III, and IV. The provided statistical model of nodal involvement in OPSCC patients trained on multi-institutional data may guide the design of clinical trials on volume-deescalated treatment of OPSCC and contribute to more personal guidelines on elective nodal treatment.

Indexed as

Disease ProgressionLymphatic MetastasisMarkov ChainsOropharyngeal NeoplasmsHumansLymph NodesModels, StatisticalMonte Carlo MethodSquamous Cell Carcinoma of Head and Neck

Identifiers

PMID38977731
PMCPMC11231166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.